RHYTHM PHARMACEUTICALS INC (RYTM)
Health Care · biotechnology · NASDAQ
Rhythm Pharmaceuticals is a biopharmaceutical company specializing in precision therapies for rare genetic and neuroendocrine disorders characterized by severe obesity and hyperphagia.
What RHYTHM PHARMACEUTICALS INC does
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing precision medicines for rare neuroendocrine diseases. The company's primary focus is on advancing melanocortin-4 receptor (MC4R) agonists to treat hyperphagia and severe obesity associated with genetic and acquired disorders of the MC4R pathway. Its lead commercial product, IMCIVREE (setmelanotide), is approved in multiple jurisdictions to manage weight and hunger in specific patient populations, including those with Bardet-Biedl syndrome, POMC, PCSK1, or LEPR deficiencies, and hypothalamic obesity.
Themes: rare disease therapeutics, obesity management, neuroendocrine disorders, precision medicine, MC4R pathway signaling
Fundamentals
- Price$89.64 as of 2026-10-08 close
- Market cap$6.2B as of 2026-08-01 (share count; price 2026-10-08)
- 1-year return-10.6% 2025-10-08 close $100.23 → 2026-10-08 close $89.64
- P/En/a negative earnings
- Net margin-103.6% FY2025, SEC XBRL
- ROE-141.3% FY2025, SEC XBRL
- Debt / equity0.49 as of 2026-09-02
- Revenue growth (YoY)+53.5% as of 2026-09-02
- Revenue CAGR (3y)+100.2% SEC XBRL
- Beta0.87 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How RYTM compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How RHYTHM PHARMACEUTICALS INC looks technically
RHYTHM PHARMACEUTICALS INC (RYTM) is trading 9.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 26.6% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 9.5% below its 200-day average, the long-term trend line — a long-term downtrend | -9.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $104.18 | $104.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $99.09 | $99.09 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 52 trading days ago — a "golden cross", a bullish long-term signal | 52 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control | 36.4 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30) | 27.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($87.01 to $101.85) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 35 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $122.20 | $122.20 |
|---|---|---|
| From the 52-week high | it is 26.6% below its 52-week high (its highest price of the past year) | -26.6% |
| Above the 52-week low | it is 20.3% above its 52-week low (its lowest price of the past year) | +20.3% |
| Below the 52-week high | it is 26.6% below its highest point of the past year | 26.6% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $122.20 (set on 2025-12-11) | $122.20 |
| Given back of the 52-week move | over the past year its closes ranged ($75.82 to $117.62), and it has recovered roughly a third of its fall from last year’s high — 33% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $101.65 to $102.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 33.1% |
| From the all-time high | it is 26.6% below its all-time high | -26.6% |
| Nearest price level | it is trading 1.3% below a resistance level at $90.79 — a price it turned at twice since 2026-04-01, most recently on 2026-04-16. Since 2024-10-08 it has 8 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $3.04 (set on 2022-05-20) | $3.04 |
| Above the all-time low | it is 2848.7% above its all-time low | +2,849% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 49th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.83 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.83 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $88.36 and $104.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $88.36 – $96.45 – $104.54 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 2.5 daily ranges below its 200-day average price (9.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.42× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-09-17 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 14 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.0 percentage points (the stock lost 11.9% while the market gained 1.0%) | -13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 25.5 percentage points (the stock lost 21.7% while the market gained 3.8%) | -25.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.4 percentage points (the stock gained 3.1% while the market gained 17.5%) | -14.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.5 percentage points (the stock lost 10.6% while the market gained 15.0%) | -25.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.3% of the share price, which is taken to mean a barrier that gives way easily. | -16.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $97.53 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -8.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $103.04 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -13.0% |
Double top, bearish — broke down · entry $99.25 · 64 sessions in
Price levels it has turned at before
RYTM last closed at $89.64 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $90.79 | Resistance | 1.3% above the last close | turned there twice · 2026-04-01 to 2026-04-16 |
| $94.49 | Resistance | 5.4% above the last close | turned there four times · 2025-07-10 to 2026-05-29 |
| $84.44 | Support | 5.8% below the last close | turned there twice · 2025-07-31 to 2026-05-19 |
| $96.64 | Resistance | 7.8% above the last close | turned there three times · 2026-01-08 to 2026-09-15 |
| $82.44 | Support | 8.0% below the last close | turned there twice · 2026-03-13 to 2026-06-02 |
| $63.27 | Support | 29.4% below the last close | turned there twice · 2024-11-27 to 2025-04-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$138.59 range $105.00 – $160.00; median $143.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RYTM
- Consensus EPS estimate-$0.7637 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.01 from -$0.7537, on 2026-08-31, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the commercial success of a single product, IMCIVREE (setmelanotide)","Significant risks associated with clinical trial outcomes for pipeline candidates like RM-718 and bivamelagon","Potential for failure to obtain or maintain regulatory approvals in new jurisdictions or for new indications"]
What changed in the latest 10-Q
AI-assisted comparison of RYTM's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) adds: IMCIVREE label expansion for acquired HO approved by U.S. FDA on March 19, 2026
- Newer filing (2026-05-05) adds: European Commission approved similar expansion on April 30, 2026
- Newer filing (2026-05-05) adds: TRANSCEND trial details - 142 patients total, 94 on setmelanotide vs 48 on placebo, -18.4% placebo-adjusted BMI reduction
- Newer filing (2026-05-05) adds: Mean BMI change from baseline: -15.8% for setmelanotide vs +2.6% for placebo at 52 weeks (p<0.0001)
- Newer filing (2026-05-05) adds: Common adverse events listed (skin hyperpigmentation, nausea, vomiting, headache affecting >20% of participants)
- Newer filing (2026-05-05) adds: Japanese New Drug Application (JNDA) for setmelanotide for acquired HO accepted and under review by PMDA as of May 5, 2026
- Newer filing (2026-05-05) adds: Anticipation of PMDA decision in second half of 2026 with expected commercial launch thereafter
- Removed:
- Older filing (2025-11-04) contains reference to FDA approval for patients aged 4 years and older with acquired HO - removed in newer filing which specifies FDA approvals more broadly
- Older filing (2025-11-04) states FDA approval for patients aged 2 years and older; newer filing (2026-05-05) specifies 4 years and older for acquired HO
- Older filing (2025-11-04) references FDA-approved test for genetic variants; newer filing (2026-05-05) uses 'genetic testing demonstrating' instead
- Older filing (2025-11-04) includes section on acquired hypothalamic obesity disease definition and TRANSCEND trial announcement from April 7, 2025 - not present in newer filing excerpt
- Older filing (2025-11-04) references FDA acceptance of sNDA on August 20, 2025 and PDUFA goal date of December 20, 2025 - not present in newer filing
- Reworded:
- Older filing states FDA approval for 'patients aged 2 years and older' for syndromic/monogenic obesity; newer filing specifies '4 years and older with acquired HO' and '2 years and older' for other indications (BBS, POMC, PCSK1, LEPR)
- Older filing references 'an FDA-approved test demonstrating variants'; newer filing states 'genetic testing demonstrating variants'
- Newer filing adds detail about marketing approval in Japan and timing thereof in the forward-looking statements list; older filing did not include this specific reference
- Older filing's forward-looking statements include reference to '(including PDUFA goal dates and Type II variation submissions)' - removed in newer filing
- Notes:
- Newer filing text appears truncated at the end ('expect commercial launch by the'); complete comparison limited by incomplete text
- Older filing text also appears truncated ('Additionally, th'); full comparison of later sections not possible
- Comparison focuses on the provided excerpts; full MD&A sections may contain additional changes not visible in truncated texts
Risk Factors
- Added:
- In newer filing: reference to 'the United Kingdom' separately from 'EU' in commercialization description
- In newer filing: added 'worldwide' to describe commercial activities transition ('capable of supporting commercial activities worldwide')
- Removed:
- Removed from newer filing: 'We were incorporated in February 2013' (incorporation date statement)
- Removed from newer filing: 'To date we have generated approximately $365.1 million of revenue from product sales' (specific revenue figure)
- Removed from newer filing: detailed FDA approval indication language ('syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency...' and variant interpretation details)
- Removed from newer filing: detailed EC/MHRA/Health Canada approval language with specific age requirements and variant terminology
- Removed from newer filing: 'and we continue to collaborate with authorities to achieve access in additional markets' (collaboration statement)
- Removed from newer filing: 'and we may not be successful in such transition' statement about commercial transition
- Removed from newer filing: three-month and nine-month loss comparisons ('$52.9 million and $43.6 million, for the three months ended September 30, 2025 and 2024, respectively. Our net losses were $149.0 million and $217.3 million for the nine months ended September 30, 2025 and 2024, respectively')
- Removed from newer filing: 'As of September 30, 2025, we had an accumulated deficit of $1.3 billion'
- Removed from newer filing: 'There can be no assurance that regulatory approvals will be received or if received that they will be received when anticipated' (assurance language for CHI program)
- Reworded:
- Changed from 'capable of supporting commercial activities' to 'capable of supporting commercial activities worldwide'
- Changed from 'Regulatory approvals may not be received when anticipated or not at all' to 'Regulatory approvals may not be received when anticipated or not at all and ultimately we may fail to realize the anticipated benefits...' (moved from CHI-specific to broader statement in newer filing)
- Net loss figures updated from Q3 2025 comparatives ($52.9M and $43.6M for three months) to Q1 2026 comparatives ($55.6M and $49.5M for three months)
- Accumulated deficit updated from '$1.3 billion' as of September 30, 2025 to '$1,407.5 million' as of March 31, 2026
- Notes:
- The newer filing text appears truncated at the end ('Our ability to become profitable depends upon our ability to generate revenue...'), preventing full comparison of subsequent content
- Comparison is between Q1 2026 filing (March 31, 2026) and Q3 2025 filing (September 30, 2025), representing different fiscal periods
- Multiple numerical updates reflect passage of time between reporting periods rather than policy changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 20 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 5 sells ($5M) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 20 sells ($29M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 22 sells ($33M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RYTM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RYTM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,442,856
- Reported value $1,381,520,142
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RYTM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RYTM had 10,287,811 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RYTM had 14.9% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.06 days to cover at the same settlement.
- Reported short interest (shares) 10,287,811
- Short interest (% of shares outstanding) 14.9%
- Prior settlement (shares) 10,303,031
- Reported change -0.15%
- Days to cover (reported) 20.06
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Viking Therapeutics (VKTX)
- Amgen (AMGN)
- Zealand Pharma (ZEAL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RYTM vs…
RHYTHM PHARMACEUTICALS INC is found in…
Frequently asked questions
What does RHYTHM PHARMACEUTICALS INC (RYTM) do?
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing precision medicines for rare neuroendocrine diseases. The company's primary focus is on advancing melanocortin-4 receptor (MC4R) agonists to treat hyperphagia and severe obesity associated with genetic and acquired disorders of the MC4R pathway.
What sector is RHYTHM PHARMACEUTICALS INC (RYTM) in?
RHYTHM PHARMACEUTICALS INC (RYTM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are RHYTHM PHARMACEUTICALS INC's (RYTM) competitors?
Notable peers of RHYTHM PHARMACEUTICALS INC (RYTM) include Eli Lilly, Novo Nordisk, Viking Therapeutics, Amgen and Zealand Pharma. This peer set is informational only — not financial advice.
Is RHYTHM PHARMACEUTICALS INC (RYTM) overbought or oversold right now?
RHYTHM PHARMACEUTICALS INC (RYTM) is currently in oversold territory (its 14-day RSI is 28, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RYTM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.